目的 探讨玉泉颗粒联合恩格列净片治疗2型糖尿病的临床疗效。方法 选取2020年7月—2022年6月上海建工医院收治144例2型糖尿病患者，按照随机数字表法将所有患者分为对照组和治疗组，每组各72例。对照组口服恩格列净片，1片/次，1次/d；治疗组在对照组治疗基础上口服玉泉颗粒，1袋/次，4次/d。两组连续治疗1个月。观察两组的临床疗效，比较两组的空腹血糖（FPG）、糖化血红蛋白（HbA1c）、平均血糖（MBG）、餐后血糖波动幅度（PPGE）、血糖水平标准差（SDBG）、胰岛素抵抗指数（HOMA-IR）、胰岛β细胞功能指数（HOMA-β）以及血清晚期氧化蛋白终产物（AOPP）、糖基化终末产物（AGES）、氧化型低密度脂蛋白受体-1（LOX-1）水平。结果 治疗后，治疗组总有效率94.44%高于对照组总有效率81.94%，组间比较差异显著（P＜0.05）。治疗后，两组FPG、HbA1c、MBG、PPGE、SDBG低于治疗前（P＜0.05）；治疗组的MBG、PPGE、SDBG低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组HOMA-IR低于治疗前，HOMA-β高于治疗前（P＜0.05）；治疗组的HOMA-IR低于对照组，HOMA-β高于对照组（P＜0.05）。治疗后，两组的血清AOPP、AGES、LOX-1水平低于治疗前（P＜0.05），且治疗组血清AOPP、AGES、LOX-1水平较对照组低（P＜0.05）。结论 玉泉颗粒联合恩格列净片治疗2型糖尿病的临床疗效确切，能改善血糖波动和胰岛素β细胞功能，降低氧化应激反应。

Objective To investigate the clinical efficacy of Yuquan Granules combined with Empagliflozin Tablets in treatment of type 2 diabetes mellitus. Methods Patients (114 cases) with type 2 diabetes mellitus in Shanghai Construction Group Hospital from July 2020 to June 2022 were divided into control and treatment groups according to the random number table method, and each group had 72 cases. Patients in the control group were po administered with Empagliflozin Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Yuquan Granules on the basis of the control group, 1 bag/time, four times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and the FPG HbA1c, MBG, PPGE, SDBG, HOMA-IR, and HOMA-β, and the levels of AOPP, AGES, and LOX-1 in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.44% higher than 81.94% of the control group, and there was a significant difference between groups (P < 0.05). After treatment, FPG, HbA1c, MBG, PPGE, and SDBG in two groups were lower than those before treatment (P < 0.05). MBG, PPGE, and SDBG in the treatment group were lower than those in the control group, and the difference was statistically significant (P < 0.05). After treatment, HOMA-IR in two groups was lower than before treatment, but HOMA-β in two groups was higher than before treatment (P < 0.05). HOMA-IR in treatment group was lower than that in control group, but HOMA-β in treatment group was higher than that in control group (P < 0.05). After treatment, the serum levels of AOPP, AGES, and LOX-1 in two groups were lower than those before treatment (P < 0.05), and the serum levels of AOPP, AGES, and LOX-1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Yuquan Granules combined with Empagliflozin Tablets has clinical curative effect in treatment of type 2 diabetes mellitus, can improve blood sugar fluctuation and insulin beta cell function, reduce oxidative stress.

R977

上海市虹口区卫生计划生育委员会医学科研课题（1503-23）